Deep learning signature of brain [18F]FDG PET associated with cognitive outcome of rapid eye movement sleep behavior disorder
An objective biomarker to predict the outcome of isolated rapid eye movement sleep
behavior disorder (iRBD) is crucial for the management. This study aimed to investigate …
behavior disorder (iRBD) is crucial for the management. This study aimed to investigate …
The putaminal abnormalities on 3.0 T magnetic resonance imaging: can they separate parkinsonism-predominant multiple system atrophy from Parkinson's disease?
J Feng, B Huang, WQ Yang, Y Zhang… - Acta …, 2015 - journals.sagepub.com
Background The putaminal abnormalities detected on 1.5 T magnetic resonance imaging
(MRI), such as putaminal atrophy, slit-like hyperintense rim, and hypointensity in the …
(MRI), such as putaminal atrophy, slit-like hyperintense rim, and hypointensity in the …
[HTML][HTML] Current management and emerging therapies in multiple system atrophy
MR Burns, NR McFarland - Neurotherapeutics, 2020 - Elsevier
Multiple system atrophy (MSA) is a progressive neurodegenerative disease variably
associated with motor, nonmotor, and autonomic symptoms, resulting from putaminal and …
associated with motor, nonmotor, and autonomic symptoms, resulting from putaminal and …
Metabolic pattern analysis of 18F-FDG PET as a marker for Parkinson's disease: a systematic review and meta-analysis
SC Gu, Q Ye, CX Yuan - Reviews in the Neurosciences, 2019 - degruyter.com
A large number of articles have assessed the diagnostic accuracy of the metabolic pattern
analysis of [18F] fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in …
analysis of [18F] fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in …
[HTML][HTML] The metabolic activity of caudate and prefrontal cortex negatively correlates with the severity of idiopathic Parkinson's disease
Positron emission tomography (PET) scan with tracer [18 F]-fluorodeoxy-glucose (18 F-FDG)
is widely used to measure the glucose metabolism in neurodegenerative disease such as …
is widely used to measure the glucose metabolism in neurodegenerative disease such as …
Annual change in Friedreich's ataxia evaluated by the Scale for the Assessment and Rating of Ataxia (SARA) is independent of disease severity
C Marelli, J Figoni, P Charles, M Anheim… - Movement …, 2012 - Wiley Online Library
Background: The objective of the study was to evaluate the sensitivity to change of the Scale
for the Assessment and Rating of Ataxia (score, 0–40) in Friedreich's ataxia. Methods: This …
for the Assessment and Rating of Ataxia (score, 0–40) in Friedreich's ataxia. Methods: This …
A new era of clinical dopamine transporter imaging using 123I-FP-CIT
E Park - Journal of nuclear medicine technology, 2012 - Soc Nuclear Med
123I-labeled 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-
CIT) was approved for clinical use in 2011 by the Food and Drug Administration. 123I-FP …
CIT) was approved for clinical use in 2011 by the Food and Drug Administration. 123I-FP …
The pimple sign of progressive supranuclear palsy syndrome
Background Some patients with progressive supranuclear palsy syndrome (PSPS)
demonstrate a focal area of midbrain hypometabolism on FDG-PET scans which we call the …
demonstrate a focal area of midbrain hypometabolism on FDG-PET scans which we call the …
[PDF][PDF] Roles of facilitative glucose transporter GLUT1 in [18F] FDG positron emission tomography (PET) imaging of human diseases
SG Patching - J Diagn Imaging Ther, 2015 - openmedscience.com
The facilitative glucose transport protein GLUT1 has important roles in positron emission
tomography (PET) imaging of human diseases. GLUT1 has widespread expression and …
tomography (PET) imaging of human diseases. GLUT1 has widespread expression and …
[图书][B] Neuroimmune pharmacology
T Ikezu, HE Gendelman - 2016 - books.google.com
The second edition of Neuroimmune Pharmacology bridges the disciplines of neuroscience,
immunology and pharmacology from the molecular to clinical levels with particular thought …
immunology and pharmacology from the molecular to clinical levels with particular thought …